Palabras clave: Poloxamer 238. Reacciones inducidas por Poloxamer. Activación del Complemento. Hipersensibilidad mediada por IgE.
We present a clinical case of anaphylaxis due to poloxamer 238. Poloxamers are recognized pharmaceutical excipients that can be used in micellar form to increase both the solubility and the stability of drugs. In addition to their use in drug delivery, poloxamers have also been reported to sensitize drug-resistant cancers to some antineoplastic drugs, thus increasing transport of the drugs across the blood-brain barrier and enhancing oral bioavailability [1] .
The patient was a 59-year-old woman, with a history of bronchial allergic asthma and sensitization to olive and Parietaria pollen.
In November 2016, she was diagnosed with breast cancer. During the radiological examination to detect a sentinel lymph node, a marker with Tc99m (Nanocoll) was administered intravenously. In less than 15 minutes, the patient began to experience itching and intense erythema in the groins, neck, mouth, and lips, followed by swelling of the tongue, dizziness, sweating, and intense dyspnea. She needed emergency care, which took the form of epinephrine, dexchlorpheniramine, and methylprednisolone. The patient was then transferred to hospital, where she recovered after hours of treatment and observation in the emergency department.
Intravenous Nanocoll is a radiopharmaceutical containing Tc99m in the form of sodium pertechnetate with nanocolloid human serum albumin and poloxamer 238.The other excipients are anhydrous glucose, stannous chloride dihydrate, sodium phosphate, anhydrous sodium phytate, and nitrogen.
The results of skin prick testing and intradermal testing with human albumin were negative. Skin prick testing and intradermal testing (1:1000) with poloxamer 238 were positive ( Figure) .
The results of prick and intradermal testing with poloxamer 238 were also negative in 5 controls.
We then performed dot-blot IgE-immunodetection, which yielded negative results. No specific IgE binding to the material analyzed was detected [2] , although specific IgE to other pharmaceutical excipients has been reported using this technique [3] .
A subsequent histamine release test showed that 22 ng/mL of histamine was released when poloxamer 238 was added to the patient's basophils, in comparison with 14 ng/mL, when we simply added the buffer that accompanies the technique (negative control). Therefore, the release of histamine generated with the drug that caused the symptoms exceeded the positivity cut-off of the technique (15 ng/mL), and the result of the test was considered positive. 7% HClO 4 was used as positive control [4] [5] [6] .
Adverse non-IgE-mediated hypersensitivity reactions have been described following intravenous injection of poloxamer 188-based pharmaceuticals, presumably via complement activation [7] .
To our knowledge, we present the first case of anaphylaxis due to poloxamer 238 administered with a radiopharmaceutical causing clinical symptoms and in which histamine release was demonstrated.
We were unable to demonstrate specific IgE binding using the dot-blot technique, although the positivity of the skin test suggests that an IgE-mediated mechanism could be involved.
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The authors declare that no funding was received for the present study. Dupilumab, a human monoclonal antibody against interleukin-4 receptor a, acts by inhibiting the signaling of interleukin-4 and interleukin-13, both of which are type 2 cytokines that may be important drivers of allergic or atopic diseases such as atopic dermatitis (AD) [1] . Dupilumab is the first biological therapy to be approved for treatment of moderate-to-severe AD in adults who are candidates for systemic therapy. Administration of dupilumab improves the signs and symptoms of AD, including pruritus and anxiety and depression, and enhances patient quality of life [2, 3] . A reassuring safety profile has been established, with conjunctivitis being the most significant safety signal [2] [3] [4] . We describe a patient with severe AD treated with dupilumab who developed alopecia areata within 6 weeks of his first exposure.
A 31-year-old white man with a 7-year history of severe AD and no other relevant past or family history presented with patches of hair loss on his anterior scalp. The patient had undergone previous treatment for AD consisting of phototherapy, topical and oral corticosteroids, cyclosporine, and azathioprine, although his response was poor. He was started on dupilumab at 600 mg subcutaneously followed by 300 mg subcutaneously every 2 weeks. After 6 weeks of treatment, his AD improved significantly; however, he noted hair loss in patches on his anterior scalp. Determination of the serum concentration of antithyroid antibodies, thyroglobulin, and thyroperoxidase yielded negative results. Thyroidstimulating hormone, T3, and free T4 determinations were also found to be normal. The results of a biopsy indicated alopecia areata with epidermal changes suggesting atopic dermatitis (areas of focal epidermal inflammation with exocytosis, spongiosis, and parakeratosis, which present as deep and patchy perifollicular lymphocytic infiltrate and frequent fibrotic tracts). The patient was diagnosed with alopecia areata, treatment with intralesional triamcinolone was initiated, and dupilumab was continued. Follow-up is required to assess the response of alopecia to corticosteroids.
